AVIR: Atea Pharmaceuticals Amount of Cash per Share

Corporate emblem and logo of Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals maintains stability through patents on its purine nucleotide platform and a strong balance sheet. The cash-per-share structure demonstrates a level of financial autonomy, where the indicator value reaches 2.38. The company develops convenient tablet-form antivirals for the treatment of hepatitis C and COVID, while simultaneously implementing ESG standards through safe chemical disposal and cold chain logistics optimization.

AVIR (Atea Pharma) Cash per Share history from 07/04/2022 to 11/20/2026

Analytical breakdowns for Atea Pharmaceuticals

- price and consensus price forecast:
- cash position and cash flow details:
Comprehensive company analysis:AVIR Atea Pharmaceuticals Inc
Core merchandise of ateapharma.com

Cash per share reflects the volume of liquidity attributable to a single share, which determines the business's autonomy from borrowed capital and its level of financial stability. By analyzing the cash per share trend, an investor assesses the ability of Atea Pharmaceuticals (AVIR) to fund the development of innovative antiviral molecules using its own reserves until their commercialization and entry into a stable market.